SNDY Could Deliver Massive Gains Today. Take Advantage of This Tiny Float Alert!
This stock is infused with insane potential.
My new pick is all about potential. What kind of potential exactly? Long-term? No. I know a lot of my readers focus on quick profits and want to get in and out quickly. That’s where my new pick shines.
What I’m talking about here is breakout potential. Let’s draw parallels so I can show what I’m talking about. Over the past six weeks I’ve alerted a few breakout candidates. One gained 120% in a single day and the other gained a whopping 248% in one day as well.
Well, they both resemble this pick to a great degree. The key factor? The tiny float.
Every stock that I’ve alerted that gained over 100% in a single day had a small float. Remember, a float represents the number of shares available to the public. The less shares available and the higher the demand the more likely share prices are to skyrocket.
Solos Endoscopy, Inc. (OTCPINK: SNDY)
I loved everything about SNDY when I stumbled across it. It’s rated as a BUY across the board according to Barchart.com and when you dig into the numbers it’s not hard to see why.
Since hitting a 52-week low In October 2015 the play has rallied 2233%!
Even more unbelievable is the fact that despite the very clear breakouts, traders can still extract serious upside potential from a company that is trading at .07.
And get this, SNDY has reached a high of .15 over the last 12 months so there is little debate about how undervalued an opportunity it is at current levels.
Momentum is unquestionable and as of writing SNDY has surpassed both its 20 DMA and 50 DMA.
The chart sort of says it all but you can also use an uptrending RSI of 57 as your benchmark for upside opportunity.
Investors are pouring into the play ever since SNDY got some pretty positive coverage in November last year.
I believe that with an uptrending and bullish chart setup you can extract maximum gain potential… And you do it all for just .07.
That’s a bargain if I’ve ever seen one. I mean, 57 RSI on a 15-cent 12-month high at this level won’t come around often.
Start your research pm this gem ASAP, the clock is ticking.
Here’s a link to the chart: http://www.barchart.com/interactive_charts/stocks/SNDY
SNDY (Solos Endoscopy, Inc.) is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office.
US Medical Device Sector Continues Strong — $133 Billion In 2016
The United States remains the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016. The U.S. market value represented about 38 percent of the global medical device market in 2012. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $44 billion in 2012, a more than 7 percent increase from the previous year.
There are more than 6,500 medical device companies in the U.S., mostly small and medium-sized enterprises (SMEs). More than 80 percent of medical device companies have fewer than 50 employees, and many (notably innovative start-up companies) have little or no sales revenue. Medical device companies are located throughout the country, but are mainly concentrated in regions known for other high-technology industries, such as microelectronics and biotechnology. The states with the highest number of medical device companies include California, Florida, New York, Pennsylvania, Michigan, Massachusetts, Illinois, Minnesota and Georgia. Other states with significant sector employment include Washington, Wisconsin, and Texas.
Solos Endoscopy, Inc. Completes Capital Restructuring Initiative
SNDY announced that the company has completed a capital restructuring initiative as part of a previously announced recapitalization plan in order to position itself for growth over the next twelve months. The restructuring involved a common stock consolidation that took effect September 23, 2015. As a result of this announcement, the stock symbol will be changed temporarily to SNDYD for a period of 20 business days after September 23, 2015.
“The recapitalization is an effort by management to give the market an opportunity to recognize the true value of our company and rebuild shareholder value. Solos is a Company who has been recognized by physicians who use their instruments Nationwide. It is our hope that recognition will be shared by the market in the coming months,” stated Robert Segersten, President Solos Endoscopy.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to carry the CE Mark on its entire MammoView(R) instrument line. Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com).
To learn more about SNDY please visit their website: http://www.solosendoscopy.com/
Make your move on SNDY now.
We have been compensated $12.5k cash via bank wire by a third party, ACN, LLC, to conduct investor relations advertising and marketing for SNDY. Stellar Media’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.